INS and type 1 diabetes mellitus: Compared with Thabit and colleagues' study of closed-loop insulin delivery versus sensor-augmented pump therapy in patients with type 1 diabetes and HbA1c between 7·5% and 10·0% (58–86 mmol/mol),13 our study had more pronounced relative reductions in the proportion of time with glucose concentration below 3·9 mmol/L (19% vs 50%) and hypoglycaemia burden (39% vs 73%).